Men having sex with men and the HPV vaccine in France: A low vaccine coverage that may be due to its infrequent proposal by physicians |
| |
| Institution: | 1. Service des Maladies Infectieuses, Centre hospitalier universitaire Grenoble Alpes, Grenoble, France;2. Fédération d’infectiologie multidisciplinaire de l’arc alpin, Université Grenoble Alpes, Grenoble, France;3. Institut de Biologie Structurale, “Virus humains persistants” Team, UMR 5075 CEA-CNRS-UGA, Grenoble, France;1. Regional HPV LabNet Reference Laboratory, Centre for Women’s Infectious Diseases, The Royal Women’s Hospital, Parkville 3052, Victoria, Australia;2. Murdoch Childrens Research Institute, Parkville 3052, Victoria, Australia;3. Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville 3050, Victoria, Australia;4. VCS Population Health, VCS Foundation, East Melbourne 3002, Victoria, Australia;5. VCS Pathology, VCS Foundation, Carlton 3053, Victoria, Australia;6. Department of Anatomical Pathology, The Royal Women’s Hospital, Parkville 3052, Victoria, Australia;7. Department of Medicine, The University of Melbourne, Royal Melbourne Hospital, Parkville 3050, Victoria, Australia;8. Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville 3050, Victoria, Australia;9. Melbourne School of Population and Global Health, The University of Melbourne, Parkville 3052, Victoria, Australia;1. INSERM CIC 1417, F-CRIN, I REIVAC, Assistance Publique- Hôpitaux de Paris, Hôpital Cochin, Paris, France;2. INSERM, Sorbonne Université, Institut Pierre Louis d’Épidémiologie et de Santé Publique, Paris, France;3. GPIP, Groupe de Pathologie Infectieuse Pédiatrique, Paris, France;4. AFPA, Association Française de Pédiatrie Ambulatoire, Saint-Germain-en-Laye, France;5. Association Clinique et thérapeutique Infantile, du Val de Marne, Saint-Maur des Fossés, France;6. Department of Neonatology, CHI Creteil, Creteil, France;7. Université de Paris, Faculté de médecine Paris Descartes, Paris, France;1. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA;2. Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA;1. The Kirby Institute, University of New South Wales, Sydney, Australia;2. Regional HPV LabNet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, Victoria, Australia;3. Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia;4. Murdoch Children’s Research Institute, Parkville, Victoria, Australia;5. RPA Sexual Health and Central Clinical School, University of Sydney, Sydney, Australia;6. Melbourne Sexual Health Centre, Alfred Health, Carlton, Melbourne, Victoria, Australia;7. Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia;8. Department of Microbiology and Infectious Diseases, Royal Women''s Hospital, Parkville, Melbourne, Victoria, Australia;9. St Vincent’s Hospital, Sydney, Australia;10. Western Sydney Sexual Health Centre, University of Sydney, Sydney, Australia;1. Department of Obstetrics and Gynecology, College of Medicine, United Arab Emirates University, Al Ain, United Arab Emirates;2. College of Medicine and Health Sciences, United Arab Emirates University, United Arab Emirates |
| |
| Abstract: | IntroductionIn France, the human papilloma (HPV) vaccine is recommended to all female adolescents, and since 2016 to men having sex with men (MSM) under the age of 27. Here, we aimed to explore HPV vaccine coverage in adult MSM living in France.MethodsWe elaborated an anonymous online questionnaire targeting MSM and disseminated it between October 7, 2018 and January 15, 2019 by various means, including a Facebook® discussion forum for pre-exposure prophylaxis (PrEP) users.ResultsOverall, 2094 participants completed the questionnaire (mean age 35.4 ± 11 years); 25.8% were in the age class targeted by the HPV vaccine recommendation; 16.1% were in a PrEP program. On a 1–10 scale, they evaluated being “in favor of vaccination” at a median of 10, and general vaccine usefulness and harmfulness at medians of 10 and 2, respectively; 62.4% considered that the HPV vaccine was rather not or not at all dangerous. Those using PrEP had better perceptions of vaccination in general and of the HPV vaccine in particular. For the 1728 participants with a family physician, he/she had proposed the HPV vaccine in 9.9% of cases (9.1% of those in the targeted age class <27 years]). Overall, 1994 knew their HPV vaccine status; 8.0% had received at least 1 dose of the vaccine, including 17.9% of those in the targeted age class (and 52.2% among the 40 participants in this age group who received PrEP). When the 1935 participants who declared to be unvaccinated against HPV were asked whether they would accept to be vaccinated, 34.4% answered “rather yes” and 45.5% “definitely yes”.ConclusionHPV vaccine coverage is low among French MSM. Our results suggest that this trend has more to do with the infrequent proposals made by clinicians than with negative vaccine perceptions. |
| |
| Keywords: | Vaccine HPV Vaccine coverage MSM |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
